Literature DB >> 24677604

D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse.

Stefan G Hofmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24677604      PMCID： PMC4006201          DOI： 10.1002/da.22257

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN： 1091-4269            Impact factor:   6.505


× No keyword cloud information.
  12 in total

Review 1.  D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update.

Authors:  Stefan G Hofmann; Alice T Sawyer; Anu Asnaani
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Augmentation of exposure therapy with post-session administration of D-cycloserine.

Authors:  Candyce D Tart; Pamela R Handelsman; Lindsey B Deboer; David Rosenfield; Mark H Pollack; Stefan G Hofmann; Mark B Powers; Michael W Otto; Jasper A J Smits
Journal:  J Psychiatr Res       Date:  2012-10-23       Impact factor: 4.791

3.  D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder.

Authors:  Stefan G Hofmann; Jasper A J Smits; David Rosenfield; Naomi Simon; Michael W Otto; Alicia E Meuret; Luana Marques; Angela Fang; Candyce Tart; Mark H Pollack
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

4.  D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia.

Authors:  Jasper A J Smits; David Rosenfield; Michael W Otto; Mark B Powers; Stefan G Hofmann; Michael J Telch; Mark H Pollack; Candyce D Tart
Journal:  Biol Psychiatry       Date:  2013-01-16       Impact factor: 13.382

5.  D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions.

Authors:  Jasper A J Smits; David Rosenfield; Michael W Otto; Luana Marques; Michelle L Davis; Alicia E Meuret; Naomi M Simon; Mark H Pollack; Stefan G Hofmann
Journal:  J Psychiatr Res       Date:  2013-07-16       Impact factor: 4.791

Review 6.  Enhancing exposure-based therapy from a translational research perspective.

Authors:  Stefan G Hofmann
Journal:  Behav Res Ther       Date:  2007-06-17

Review 7.  Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders.

Authors:  Stefan G Hofmann
Journal:  Clin Psychol Rev       Date:  2007-05-03

8.  D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables.

Authors:  Jasper A J Smits; Stefan G Hofmann; David Rosenfield; Lindsey B DeBoer; Paul T Costa; Naomi M Simon; Conall O'Cleirigh; Alicia E Meuret; Luana Marques; Michael W Otto; Mark H Pollack
Journal:  J Consult Clin Psychol       Date:  2013-08-12

9.  Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

Authors:  Stefan G Hofmann; Alicia E Meuret; Jasper A J Smits; Naomi M Simon; Mark H Pollack; Katherine Eisenmenger; Michael Shiekh; Michael W Otto
Journal:  Arch Gen Psychiatry       Date:  2006-03

10.  D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders.

Authors:  Stefan G Hofmann; Jade Q Wu; Hannah Boettcher
Journal:  Biol Mood Anxiety Disord       Date:  2013-06-15
View more
  15 in total

Review 1.  Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.

Authors:  Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack
Journal:  Biol Psychiatry       Date:  2015-09-25       Impact factor: 13.382

Review 2.  Neurochemical mechanisms for memory processing during sleep: basic findings in humans and neuropsychiatric implications.

Authors:  Gordon B Feld; Jan Born
Journal:  Neuropsychopharmacology       Date:  2019-08-23       Impact factor: 7.853

Review 3.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

4.  Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale.

Authors:  Stefan G Hofmann; Joseph K Carpenter; Michael W Otto; David Rosenfield; Jasper A J Smits; Mark H Pollack
Journal:  Contemp Clin Trials       Date:  2015-06-23       Impact factor: 2.226

Review 5.  D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update.

Authors:  Stefan G Hofmann; Michael W Otto; Mark H Pollack; Jasper A Smits
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

6.  N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents.

Authors:  Ovsanna Leyfer; Aubrey Carpenter; Donna Pincus
Journal:  Child Psychiatry Hum Dev       Date:  2019-04

Review 7.  An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Biol Psychiatry       Date:  2015-06-15       Impact factor: 13.382

8.  Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Authors:  Carolyn I Rodriguez; Michael Wheaton; Jordana Zwerling; Shari A Steinman; Danae Sonnenfeld; Hanga Galfalvy; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2016-03       Impact factor: 4.384

Review 9.  Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders.

Authors:  Rasmita Ori; Taryn Amos; Hanna Bergman; Karla Soares-Weiser; Jonathan C Ipser; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2015-05-10

10.  Neuroenhancement of Exposure Therapy in Anxiety Disorders.

Authors:  Stefan G Hofmann; Elizabeth A Mundy; Joshua Curtiss
Journal:  AIMS Neurosci       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.